Vaccinia virus (ATCC® VR-2043)

Classification: Poxviridae, Orthopoxvirus  /  Product Format: frozen

Classification Poxviridae, Orthopoxvirus
Agent Vaccinia virus
Strain vP-9 [recombinant Vaccinia virus]
Applications
produces protein hemagglutinin, serotype H1
Biosafety Level 2
Product Format frozen
Storage Conditions -70°C or colder
Comments
vP-9 (ATCC VR-2043) and vP-10 (ATCC VR-2044) contain the same insert but in opposite orientations.
Recombinant vaccinia containing influenza HA gene. HA antigen is expressed in vivo.
Recombinant vaccinia containing influenza HA gene. HA antigen is expressed in vivo.
Expresses the hemagglutinin gene (serotype H1) and can be used in the production of antibodies against this protein.
Effect on Host
Yes, in vitro effects: Cytopathic effects in tissue culture
CPE
Effect on Host
Yes, in vitro effects: Cytopathic effects in tissue culture
CPE
Name of Depositor E Paoletti
Special Collection Patent
References

Paoletti E, Panicali D. Modified vaccinia virus. US Patent 4,603,112 dated Jul 29 1986

Paoletti E, Panicali D. Method for immunizing animals with synthetically modified vaccinia virus. US Patent 4,722,848 dated Feb 2 1988

Panicali D, et al. Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J. Virol. 37: 1000-1010, 1981. PubMed: 6262520